First-line osimertinib for poor performance status patients with EGFR mutation-positive non-small cell lung cancer: A prospective observational study

Satoshi Igawa, Tomoya Fukui, Masashi Kasajima, Taihei Ono, Takahiro Ozawa, Mikiko Kakegawa, Seiichiro Kusuhara, Takashi Sato, Yoshiro Nakahara, Hisashi Mitsufuji, Jiichiro Sasaki, Katsuhiko Naoki